DURECT Announces Amendment to Licensing Agreement with Sandoz Related to POSIMIR(R) (SABER(R)-Bupivacaine)

CUPERTINO, Calif., May 9, 2018 -- (Healthcare Sales & Marketing Network) -- DURECT Corporation (Nasdaq: DRRX) today announced it has entered into an amendment (the "Amendment") to the development and commercialization agreement with Sandoz AG, a... Biopharmaceuticals, Drug Delivery, Surgery, Licensing DURECT, Sandoz, Novartis, POSIMIR, bupivacaine
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news